
Marksans Pharma Limited has informed the Exchange regarding a press release dated August 21, 2024, titled "Marksans Pharma Limited s wholly owned subsidiary Relonchem Limited receives Marketing Authorization for its products".
Filed with NSE ·

Marksans Pharma Limited has informed the Exchange regarding a press release dated August 21, 2024, titled "Marksans Pharma Limited s wholly owned subsidiary Relonchem Limited receives Marketing Authorization for its products".
6ix hasn’t read this filing yet.
Marksans Pharma Limited on 6ix
Follow Marksans Pharma into a list and get an email when it puts out news.
Follow Marksans Pharma